Technology
Health
Biotechnology
Evogene
$1.529876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.52
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.04 (2.72%) Today
+$0.01 (0.66%) After Hours
Why Robinhood?
You can buy or sell Evogene and other stocks, options, ETFs, and crypto commission-free!
About
Evogene Ltd. operates as a plant genomics company. It utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Read More It also offers a solution for crop productivity improvement through biotechnology and breeding using a technology infrastructure that is based on deep scientific understanding of plant genomics and proprietary computational capabilities. The company was founded by Amir Barzilay and Hagai Karchi in 2002 and is headquartered in Rehovot, Israel.
CEO
Employees
—
Headquarters
Rehovot, HaMerkaz
Founded
2002
Market Cap
37.86M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
13.90K
High Today
$1.51
Low Today
$1.49
Open Price
$1.49
Volume
1.27K
52 Week High
$3.32
52 Week Low
$1.39
Collections
Technology
Health
Biotechnology
2013 IPO
Asia (Non-China)
Asia
News
Seeking AlphaMay 28
Evogene Ltd. CEO Ofer Haviv on Q1 2019 Results - Earnings Call Transcript
Evogene Ltd. (NASDAQ:EVGN) Q1 2019 Earnings Conference Call May 28, 2019 9:00 AM ET Company Participants Ofer Haviv - CEO Arnon Heyman - CEO, Canonic Dorit Kreiner - CFO Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. Welcome to Evogene's First Quarter 2019 Results Conference Call. All participants are at present in listen-only mode. Following management's formal presentation, instructions will be given for the question-and-answer session. [Operator Instructions...
Price Paid on Robinhood
29% Lower
Right Now
52 Week Low
$1.39
Average Price Paid
$2.14
52 Week High
$3.32
Earnings
-$0.24
-$0.21
-$0.18
-$0.15
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 7, Pre-Market